Endo, Inc. has announced the launch of ADRENALIN (epinephrine in 0.9 percent sodium chloride injection) 8 mg/250 mL premixed bag and will begin shipping the product the week of May 19, 2025. ADRENALIN is the first FDA-approved and currently the only commercially available manufacturer-prepared epinephrine premixed IV bag.

Scott Sims, Senior Vice President and General Manager, Endo Injectable Solutions and Generics, said, “Hospital pharmacists and healthcare providers are working harder than ever, and we are committed to supporting them with ready-to-use medicines that help reduce complexity and streamline operations so they can focus on what matters most—patient care. With this new ADRENALIN premixed bag concentration, plus the additional concentrations in our pipeline, we are proud to offer options and choice through our TruDelivery portfolio."

Key product benefits include the convenience of no compounding or preparation required, a single-port IV tubing design that helps reduce the risk of inadvertent mixture, and a 24-month shelf life at room temperature.

The ADRENALIN premixed bag is part of Endo Injectable Solutions' TruDelivery product line and platform. Ready-to-use products streamline operations for hospitals by eliminating the need to prepare or transfer the product before patient administration. This may reduce waste and costs, optimise convenience and workflow, and reduce the chance for preparation error, all of which support quality patient care.

In addition to the new 8 mg/250 mL bag, Endo offers ADRENALIN 4 mg/250 mL premixed bag and plans to launch 5 mg/250 mL and 10 mg/250 mL concentrations. The company also offers ADRENALIN (epinephrine injection, USP) 1 mL single-dose and 30 mL multi-dose vials.